NBTX VS CRMD Stock Comparison
Performance
NBTX51/100
51/100
NBTX returned -7.36% in the last 12 months. Based on the other stocks in its sector with an average return of -7.41%, its performance is above average giving it a grade of 50 of 100.
CRMD100/100
100/100
CRMD returned -5.36% in the last 12 months. Based on SPY's performance of -20.65%, its performance is above average giving it a score of 100 of 100.
Sentiment
NBTX63/100
63/100
NBTX had a bullish sentiment score of 63.40% across Twitter and StockTwits over the last 12 months. It had an average of 30.90 posts, 5.83 comments, and 30.90 likes per day.
CRMD70/100
70/100
CRMD had a bullish sentiment score of 70.08% across Twitter and StockTwits over the last 12 months. It had an average of 24.93 posts, 20.56 comments, and 129.49 likes per day.
Volatility
NBTX20/100
20/100
NBTX has had a lower than average amount of volatility over the last 12 months giving it a grade of 20 of 100.
CRMD51/100
51/100
CRMD has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.
Analyst Price Targets
NBTX
"Analyst Price Targets" not found for NBTX
CRMD75/100
75/100
1 analysts offer 12-month price targets for CRMD. Together, they have an average target of 0, the most optimistic target put CRMD at 0 within 12-months and the most pessimistic has CRMD at 0.
Technicals
NBTX
"Technicals" not found for NBTX
CRMD14/100
14/100
CRMD receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
NBTX
"Earnings" not found for NBTX
CRMD10/100
10/100
CRMD has missed earnings 6 times in the last 20 quarters.
Profit
NBTX
"Profit" not found for NBTX
CRMD10/100
10/100
Out of the last 20 quarters, CRMD has had 1 profitable quarters and has increased their profits year over year on 0 of them.
All score calculations are broken down here to help you make more informed investing decisions
Nanobiotix S.A. American Depositary Shares Summary
Nasdaq / NBTX
Healthcare
Biotechnology
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
CorMedix Inc. Summary
Nasdaq / CRMD
Healthcare
Biotechnology
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare NBTX to other companies in the same or a similar industry.
